Business Wire

CA-NEAT

22.7.2020 15:02:05 CEST | Business Wire | Press release

Share
Neat Launches Subscription Service for Zoom Customers Outside the US and Announces Additional Investment from Zoom

Neat , a Norwegian company whose pioneering team have been at the cutting edge of video communications for decades, today announced its Neat as a Service (NaaS) subscription offering. NaaS makes it quick and easy for Zoom customers outside the US to deploy Neat hardware devices in their meeting spaces. Neat and Zoom have also disclosed that Zoom Video Communications, Inc. (NASDAQ: ZM) has made an additional financial investment in Neat.

"Zoom and Neat together are making it easy for customers to expand their video conferencing capabilities. Our additional investment in Neat reflects our conviction that Neat's devices are an outstanding complement to Zoom's communications platform," said Eric S. Yuan, Zoom CEO. "We believe Neat offers innovative technology that ensures Zoom customers enjoy an incredible meeting room experience."

Aligned with Zoom's recently introduced Hardware as a Service (HaaS), NaaS is provided directly by Neat and expands the reach of Zoom HaaS beyond the US, enabling Zoom customers globally to consume Neat devices. Among other things, it's an ideal solution for customers with offices and teams scattered throughout different countries, as they can ensure a consistent global experience for all users.

As the new normal forces people around the world to adapt their ways of working, both in offices and remotely, video conferencing is proving to be a key tool in supporting continued productivity and driving stronger collaboration. NaaS makes it seamless for customers with a Zoom Rooms license to equip their meeting spaces with any of Neat's world-class devices: Neat Bar and Neat Pad, and Neat Board when it begins shipping at the end of October. With easy ordering and set up, customers can quickly enjoy all the benefits of deploying Zoom Rooms the Neat way, including receiving all the latest software releases and support from Zoom.

"Zoom customers globally are transitioning back to a mix of office and remote work, and need a scalable, cost-effective way to quickly expand their Zoom deployments in their meeting spaces," said Jeff Smith, Head of Zoom Rooms, Zoom. "Neat's innovative devices deliver a great user experience and are easy to install and manage. NaaS builds on that by giving customers the purchasing flexibility and choice they need."

"Subscription models such as Neat as a Service are the future of video conferencing since they eliminate expensive up-front costs and the complexity of deployment and ongoing support," said Roopam Jain, Industry Director, Unified Communications and Collaboration at Frost and Sullivan. "Video meetings are a better way to connect and collaborate. Particularly today, users need video that just works, whether they are in their home offices or meeting rooms."

Customers currently pay for their Zoom Rooms licenses through a subscription service from Zoom. With NaaS, they can use a subscription model for Neat devices as well, making the budgeting and managing of their Zoom Rooms even simpler.

NaaS is available now at neat.no and offers a 24-month plan with flexible payment options so customers can select the plan that best suits their requirements and budget. Neat Bar subscriptions start from as low as US$ 100/mo with an annual billing option. After the initial 24-month term, customers can then choose to upgrade their Neat system for the latest model with the newest hardware technology. Customers can also easily add further Neat devices to their existing plan to keep everything on a single contract.

"Neat was designed for Zoom, with the sole purpose of delivering a delightful meeting room experience to Zoom customers. We have achieved that by providing Zoom customers around the globe with our beautifully designed, simple to set up, feature-rich devices," said Simen Teigre, Neat CEO. "NaaS is the next step in our mission, offering a flexible subscription service that allows businesses to expand their Zoom solution with Zoom Rooms in a hassle-free way."

About Neat

Neat designs simple and elegant video meeting devices that just work. The company was founded in Oslo, Norway, by a team that for decades have shaped game-changing innovations for some of the most recognized brands in video communications. All Neat products are available to buy directly online from neat.no and ship globally. Offering unique features, they are easy to set up and use, making Zoom Rooms the smoothest and best it's ever been. For more information on Zoom Rooms the Neat way, visit neat.no or @neat_no .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye